Wall Street Starts Coverage of Latigo as Analysts Back Non-Opioid Pain Pipeline
Four banks initiate coverage of Latigo after its IPO, citing LTG-001, 2027 data, and cash runway into 2028 for non-opioid pain drugs.
/ 1648 items
#XY↓
Mixed Phase 2b Results for Alumis Lupus Drug; Company Eyes Phase 3 in Subgroup
Alumis’ Phase 2b LUMUS trial of envudeucitinib missed overall SLE endpoints but showed robust responses in IFNGS-high patients. Psoriasis NDA still set for Q4 2026.
Piper Sandler Upgrades Capricor to Overweight, Lifts Target to $25 After FDA Review Extension
Capricor stock jumped after Piper Sandler turned bullish, citing a better risk-reward into the Nov. 22 FDA ruling on its DMD therapy.
Novartis Pauses Cell Therapy Trials After Three Deaths as MS Pill Succeeds in Late-Stage Studies
Three deaths halt Novartis rap-cel trials in autoimmune disease. Positive Phase 3 data for remibrutinib in relapsing MS announced the same day.
Myriad Genetics Cut to Underweight as Piper Questions Path to Profit
Piper Sandler double-downgraded MYGN, saying the current model cannot grow or cut its way to profit.
Hims & Hers Launches in Australia With Online Men’s Health and Weight-Loss Care
Hims launches nationwide men’s care in Australia after buying Eucalyptus.